How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.

Eli Lilly down 19% in May, worst month since 2009. Underperformed S&P 500 by 24%, worst since August 2000. June shows promise, historically Lilly’s strongest month. See how Matt Maley is ...

Eli Lilly has already sued some of them, alleging that these versions are illegal. Other telehealth firms and compounders are playing it safe, ceasing sales altogether. (Olympia, for example, is ...

Researchers studied results for those taking Zepbound and Wegovy. They found Zepound users lost nearly 50% more weight than Wegovy users. The study, which was funded by Zepbound maker Eli Lilly, was ...

The study was funded by Eli Lilly. ... That translates to people on Zepound losing about 20.2% of their body weight on average and those taking Wegovy losing about 13.7%.

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs ...

Eli Lilly (LLY 1.84%) and Novo Nordisk ... Ozempic, Wegovy, Mounjaro, and Zepound are all administered via injection, but the next wave of GLP-1 agonists is in development, ...

Eli Lilly (NYSE: LLY) and Novo Nordisk ... Ozempic, Wegovy, Mounjaro, and Zepound are all administered via injection, but the next wave of GLP-1 agonists is in development, ...